Predicting long-term (> or = 5 years) event-free survival in multiple myeloma patients following planned tandem autotransplants.
作者:
主题词
抗肿瘤药, 烷基化(Antineoplastic Agents, Alkylating);骨髓移植(Bone Marrow Transplantation);染色体畸变(Chromosome Aberrations);染色体, 人, 11对(Chromosomes, Human, Pair 11);染色体, 人, 13对(Chromosomes, Human, Pair 13);综合疗法(Combined Modality Therapy);无病生存(Disease-Free Survival);女(雌)性(Female);人类(Humans);Logistic模型(Logistic Models);男(雄)性(Male);美法仑(Melphalan);中年人(Middle Aged);多发性骨髓瘤(Multiple Myeloma);预后(Prognosis);存活率(Survival Rate);时间因素(Time Factors);移植, 自体(Transplantation, Autologous);β2微球蛋白(beta 2-Microglobulin)
DOI
10.1046/j.1365-2141.2002.03231.x
PMID
11841419
发布时间
2019-07-05
- 浏览22
相似文献
- 中文期刊
- 外文期刊
- 学位论文
- 会议论文